• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    ThermoGenesis Holdings Inc. filed SEC Form 8-K: Leadership Update

    7/16/24 5:18:35 PM ET
    $THMO
    Medical Specialities
    Industrials
    Get the next $THMO alert in real time by email
    thmo20240716c_8k.htm
    false 0000811212 0000811212 2024-07-15 2024-07-15
     

     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM 8-K
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of
    The Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): July 15, 2024
     
    THERMOGENESIS HOLDINGS, INC.
    (Exact Name of Registrant as Specified in Charter)
             
       
    Delaware
     
    333-82900
     
    94-3018487
             
    (State or Other Jurisdiction
     
    (Commission
     
    (IRS Employer
    of Incorporation)
     
    File Number)
     
    Identification No.)
     
       
    2711 Citrus Road, Rancho Cordova, California
     
    95742
         
    (Address of Principal Executive Offices)
     
    (Zip Code)
     
    Registrant’s telephone number, including area code: (916) 858-5100
     
    N/A
    (Former Name or Former Address, if Changed Since Last Report)
     
    Securities registered pursuant to Section 12(b) of the Act: None
     
     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
     
    Emerging growth company          ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.          ☐
     
     

     
     
    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
     
    On June 15, 2024, Jeffery Cauble, the Chief Financial Officer of ThermoGenesis Holdings, Inc. (the “Company”), resigned as an employee and officer of the Company. Such resignation was effective immediately. The Company intends to seek to obtain a replacement to serve as the Company’s principal financial and accounting officer as soon as practicable.
     
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
       
    THERMOGENESIS HOLDINGS, INC.
       
    (Registrant)
    Dated: July 16, 2024
     
    /s/ Xiaochun “Chris” Xu
       
    Xiaochun “Chris” Xu
    Chief Executive Officer
     
     
     
    Get the next $THMO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $THMO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $THMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Xu Xiaochun converted options into 7,894,737 shares (SEC Form 4)

    4 - ThermoGenesis Holdings, Inc. (0000811212) (Issuer)

    7/9/24 7:02:58 PM ET
    $THMO
    Medical Specialities
    Industrials

    Xu Xiaochun converted options into 4,113,158 shares (SEC Form 4)

    4 - ThermoGenesis Holdings, Inc. (0000811212) (Issuer)

    3/19/24 2:09:52 PM ET
    $THMO
    Medical Specialities
    Industrials

    Xu Xiaochun sold $612,000 worth of shares (600,000 units at $1.02) (SEC Form 4)

    4 - ThermoGenesis Holdings, Inc. (0000811212) (Issuer)

    11/21/23 7:30:22 AM ET
    $THMO
    Medical Specialities
    Industrials

    $THMO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ThermoGenesis Holdings Announces Third Quarter 2023 Financial Results and Provides Corporate Update

    Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., Nov. 13, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the third quarter ended September 30, 2023, and provided a corporate business update. "In October, we were pleased to have completed the build-out of our 35,500+ square foot, state-of-the-art facility in Sacramento, which represents the cornerstone of our planned business expansion into a high performance, integrated contract development and manufacturing organization (CDMO) in the cel

    11/13/23 4:05:00 PM ET
    $THMO
    Medical Specialities
    Industrials

    ThermoGenesis Holdings to Present at the H.C. Wainwright 25th Annual Global Investment Conference

    RANCHO CORDOVA, Calif., Sept. 6, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that Chris Xu, Ph.D., Chief Executive Officer, will present a company overview on Wednesday, September 13, at 4:30 pm ET, during the H.C. Wainwright 25th Annual Global Investment Conference, taking place September 11-13, 2023, in New York.  Dr. Xu will also host in-person and virtual one-on-one meetings during the event. Institutional investors who are registered for the conference can log into www.hcwevents.com to request a meeting with the company. Those interested in meeting wit

    9/6/23 8:30:00 AM ET
    $THMO
    Medical Specialities
    Industrials

    ThermoGenesis Holdings Announces Second Quarter 2023 Financial Results and Provides Corporate Update

    Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., Aug. 10, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the second quarter ended June 30, 2023, and provided a corporate business update. "Throughout the second quarter, we continued to make headway in constructing our innovative ReadyStart suites in Sacramento. The suites, to be housed in a cutting-edge 35,500+ square foot, cGMP facility, are paramount to our strategy of becoming a high-performance, integrated contract development and manuf

    8/10/23 4:05:00 PM ET
    $THMO
    Medical Specialities
    Industrials

    $THMO
    SEC Filings

    View All

    ThermoGenesis Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - ThermoGenesis Holdings, Inc. (0000811212) (Filer)

    1/6/25 5:30:21 PM ET
    $THMO
    Medical Specialities
    Industrials

    SEC Form NT 10-Q filed by ThermoGenesis Holdings Inc.

    NT 10-Q - ThermoGenesis Holdings, Inc. (0000811212) (Filer)

    8/15/24 3:53:44 PM ET
    $THMO
    Medical Specialities
    Industrials

    ThermoGenesis Holdings Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - ThermoGenesis Holdings, Inc. (0000811212) (Filer)

    8/6/24 5:20:08 PM ET
    $THMO
    Medical Specialities
    Industrials

    $THMO
    Financials

    Live finance-specific insights

    View All

    ThermoGenesis Holdings Announces Third Quarter 2023 Financial Results and Provides Corporate Update

    Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., Nov. 13, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the third quarter ended September 30, 2023, and provided a corporate business update. "In October, we were pleased to have completed the build-out of our 35,500+ square foot, state-of-the-art facility in Sacramento, which represents the cornerstone of our planned business expansion into a high performance, integrated contract development and manufacturing organization (CDMO) in the cel

    11/13/23 4:05:00 PM ET
    $THMO
    Medical Specialities
    Industrials

    ThermoGenesis Holdings Announces Second Quarter 2023 Financial Results and Provides Corporate Update

    Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., Aug. 10, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the second quarter ended June 30, 2023, and provided a corporate business update. "Throughout the second quarter, we continued to make headway in constructing our innovative ReadyStart suites in Sacramento. The suites, to be housed in a cutting-edge 35,500+ square foot, cGMP facility, are paramount to our strategy of becoming a high-performance, integrated contract development and manuf

    8/10/23 4:05:00 PM ET
    $THMO
    Medical Specialities
    Industrials

    ThermoGenesis Holdings to Announce Financial Results for the Second Quarter ended June 30, 2023 and Provide a Corporate Strategic Update

    Conference Call to be Held on August 10, 2023 RANCHO CORDOVA, Calif., Aug. 8, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the second quarter ended June 30, 2023, and provide a corporate strategic update on Thursday, August 10, 2023, after the close of trading. A conference call and webcast will follow at 1:30 p.m. PT/ 4:30 p.m. ET. To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call

    8/8/23 3:26:00 PM ET
    $THMO
    Medical Specialities
    Industrials

    $THMO
    Leadership Updates

    Live Leadership Updates

    View All

    Atlantic Therapeutics Announces the Appointment of Russell Medford MD, PhD as New US-Based Chairman

    BOSTON, July 27 2022 Appointment aligns with recognized high growth potential for INNOVO® in the US.A strong endorsement for the scientific and clinical credibility of INNOVO® as an accessible treatment for Stress Urinary Incontinence (SUI).Endorses FemTech as a high potential investment category./PRNewswire/ -- Today Atlantic Therapeutics, a Galway, Ireland and Boston, USA-based MedTech innovator, announces the appointment of Russell Medford MD, PhD as Chairman. The addition of Dr Medford to the Board is a significant step to fulfill the potential of the INNOVO® brand in the large and under-served US stress urinary incontinence (SUI) market. Dr Medford is a senior healthcare and life scien

    7/27/22 7:00:00 AM ET
    $THMO
    Medical Specialities
    Industrials

    $THMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by ThermoGenesis Holdings Inc. (Amendment)

    SC 13D/A - ThermoGenesis Holdings, Inc. (0000811212) (Subject)

    11/27/23 8:10:20 PM ET
    $THMO
    Medical Specialities
    Industrials

    SEC Form SC 13D/A filed by ThermoGenesis Holdings Inc. (Amendment)

    SC 13D/A - ThermoGenesis Holdings, Inc. (0000811212) (Subject)

    8/14/23 4:27:10 PM ET
    $THMO
    Medical Specialities
    Industrials

    SEC Form SC 13D/A filed by ThermoGenesis Holdings Inc. (Amendment)

    SC 13D/A - ThermoGenesis Holdings, Inc. (0000811212) (Subject)

    4/10/23 6:14:26 PM ET
    $THMO
    Medical Specialities
    Industrials